• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gold Moves Higher; US Consumer Sentiment Improves In December

    12/22/23 12:18:33 PM ET
    $ADN
    $ALVR
    $BMY
    $DSKE
    Industrial Machinery/Components
    Miscellaneous
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADN alert in real time by email

    U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday.

    The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&P 500 also rose, gaining, 0.28% to 4,759.82.

    Check This Out: $312M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying

     

    Leading and Lagging Sectors

     

    Utilities shares jumped by 0.9% on Friday.

    In trading on Friday, consumer discretionary shares fell by 0.4%.

     

    Top Headline

     

    The University of Michigan's consumer sentiment was revised higher to 69.7 in December versus a preliminary reading of 69.4.

     

    Equities Trading UP

     

    Karuna Therapeutics, Inc. (NASDAQ:KRTX) shares shot up 47% to $316.30. Bristol Myers Squibb & Co (NYSE:BMY) agreed to acquire Karuna Therapeutics for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

    Shares of Royalty Management Holding Corporation (NASDAQ:RMCO) got a boost, surging 49% to $2.9650 after the company said its unit Ferrox Holdings confirmed the commencement of production of titanium ferrite from its Tivani operating site.

    Daseke, Inc. (NASDAQ:DSKE) shares were also up, gaining 65% to $8.11 after the company announced it will be acquired by TFI International.

     

    Equities Trading DOWN

     

    AlloVir, Inc. (NASDAQ:ALVR) shares dropped 66% to $0.7988 after the company provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-specific T cell therapy, which targets six viral pathogens in immunocompromised individuals: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and JC virus (JCV).

    Shares of Advent Technologies Holdings, Inc. (NASDAQ:ADN) were down 35% to $0.2050 after the company announced a $2 million registered direct offering of common stock.

    Netcapital Inc. (NASDAQ:NCPL) was down, falling 34% to $0.2194 after the company announced pricing of a $4 million public offering.

    Also Check This Out: 3 Minutes To Boost Your Earnings: 3 High-Yielding Dividend Stocks In Defensive Sector From Wall Street's Most Accurate Analysts

     

    Commodities

     

    In commodity news, oil traded up 0.1% to $73.92 while gold traded up 0.7% at $2,065.20.

    Silver traded down 0.1% to $24.55 on Friday while copper fell 0.3% to $ 3.9040.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.14%, London’s FTSE 100 rose 0.04% while Spain’s IBEX 35 Index rose 0.08% The German DAX rose 0.11% French CAC 40 fell 0.03%, while Italy’s FTSE MIB Index gained 0.26%.

    The consumer confidence index in Italy climbed to 106.7 in December from 103.6 a month ago, while manufacturing confidence index fell to 95.4 in December from 96.6 in November. Spanish economy grew by 0.3% quarter-over-quarter during the third quarter.

    Producer prices in the French domestic market rose by 2.4% month-over-month in November compared to a revised 0.1% decline a month ago, while consumer confidence increased to 89 in December versus a revised 88 in the prior month.

    The British economy grew by 0.3% year-over-year in the third quarter, while current account deficit shrank to £17.2 billion in the third quarter of versus a revised £24.0 billion gap in the prior period. Retail sales in the U.K. rose by 1.3% from a month ago in November.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Friday, with Japan’s Nikkei 225 gaining 0.09%, Hong Kong’s Hang Seng Index falling 1.69% and China’s Shanghai Composite Index falling 0.13%. India’s S&P BSE Sensex, meanwhile, rose 0.34%.

    The annual inflation rate in Japan fell to 2.8% in November from 3.3% in the earlier month, while food prices in Japan increased by 7.3% from a year ago in November.

     

    Economics

     

    New orders for manufactured durable goods rose by 5.4% month-over-month in November.

    Building permits in the U.S. declined by 2.1% to an annual rate of 1.467 million in November versus the preliminary estimate of 1.460 million.

    Personal income in the U.S. rose by 0.4% month-over-month in November, while personal spending increased by 0.2% from a month ago in November.

    Core PCE prices in the U.S. rose by 0.1% from the prior month in November. However, core prices rose by 3.2% from the prior year, compared to market estimates of 3.3%.

    The University of Michigan's consumer sentiment was revised higher to 69.7 in December versus a preliminary reading of 69.4.

    Sales of new single-family houses fell by 12.2% from the prior month to an annualized rate of 590 thousand in November.

    Now Read This: Top 4 Tech Stocks That May Implode This Month

    Get the next $ADN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADN
    $ALVR
    $BMY
    $DSKE

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    1/7/2026$65.00Neutral → Buy
    UBS
    Bristol-Myers Squibb Company
    $BMY
    12/15/2025$61.00Neutral → Buy
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    12/12/2025$62.00Neutral → Buy
    Guggenheim
    Bristol-Myers Squibb Company
    $BMY
    11/13/2025$45.00Sector Perform
    Scotiabank
    Bristol-Myers Squibb Company
    $BMY
    8/5/2025$42.00Outperform → Neutral
    Daiwa Securities
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Bristol-Myers Squibb Company
    $BMY
    12/16/2024$70.00Hold → Buy
    Jefferies
    More analyst ratings

    $ADN
    $ALVR
    $BMY
    $DSKE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

    Bristol Myers Squibb (NYSE:BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company's Investor Relations website at http://investor.bms.com to view the detailed fourth quarter and full-year 2025 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb:

    2/5/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb

    OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmesMulti-year agreement with five-year initial term and option to extend Oxford, UK – 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has expanded its strategic partnership with Bristol Myers Squibb ("BMS") (NYSE:BMY), signing a new Commercial Supply Agreement (CSA) for the manufacture and supply of lentiviral vectors for BMS' CAR-T programmes. This expanded partnership builds on the existing relationship with Bristol Myers Squibb, originally announced in March 2020. Under the new agreement, OXB is expected to commence

    2/4/26 7:00:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi

    Soccer Hall-of-Famer is speaking out for the first time about his private battle with lymphoma and treatment with Breyanzi in honor of World Cancer Day Breyanzi is a personalized, CD19-directed CAR T cell therapy made from a patient's own T cells and is FDA-approved for five different cancer types, the broadest set of indications of any CD19-directed CAR T cell therapy Bristol Myers Squibb (NYSE:BMY) today announced they have teamed up with renowned goalkeeper and sports commentator Kasey Keller, who is publicly sharing his personal experience with non-Hodgkin lymphoma (NHL) for the first time. His story details a long and challenging treatment journey that ultimately led him to Breyanz

    2/4/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ALVR
    $BMY
    $DSKE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bristol-Myers upgraded by UBS with a new price target

    UBS upgraded Bristol-Myers from Neutral to Buy and set a new price target of $65.00

    1/7/26 8:28:35 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol-Myers upgraded by BofA Securities with a new price target

    BofA Securities upgraded Bristol-Myers from Neutral to Buy and set a new price target of $61.00

    12/15/25 8:58:16 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol-Myers upgraded by Guggenheim with a new price target

    Guggenheim upgraded Bristol-Myers from Neutral to Buy and set a new price target of $62.00

    12/12/25 8:34:33 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ALVR
    $BMY
    $DSKE
    SEC Filings

    View All

    SEC Form 8-K filed by Netcapital Inc.

    8-K - Netcapital Inc. (0001414767) (Filer)

    2/6/26 4:30:23 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Bristol-Myers Squibb Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

    2/5/26 7:07:45 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-1/A filed by Netcapital Inc.

    S-1/A - Netcapital Inc. (0001414767) (Filer)

    2/2/26 4:05:46 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    $ADN
    $ALVR
    $BMY
    $DSKE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Digital & Tech Off. Meyers Gregory Scott converted options into 2,543 shares and covered exercise/tax liability with 833 shares, increasing direct ownership by 9% to 21,428 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/3/26 4:40:10 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, RayzeBio Org. Hickey Benjamin converted options into 10,079 shares and covered exercise/tax liability with 3,810 shares, increasing direct ownership by 71% to 15,058 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/3/26 4:39:19 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Yale Phyllis R

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/3/26 4:36:45 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ALVR
    $BMY
    $DSKE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ALVR
    $BMY
    $DSKE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/29/25 6:14:13 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/21/25 7:09:34 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/19/25 7:19:54 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ALVR
    $BMY
    $DSKE
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

    Bristol Myers Squibb (NYSE:BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company's Investor Relations website at http://investor.bms.com to view the detailed fourth quarter and full-year 2025 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb:

    2/5/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Netcapital Acquires Iverson Design Assets and Proprietary AI Design Technology Suite

    Accelerates Transformation into Tokenization and Digital Asset Platform BOSTON, MA, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)), a digital private capital markets ecosystem, today announced the acquisition of the assets of Iverson Design, LLC, a creative studio and developer of AI-powered design and visualization tools. Led by multimedia and AI designer Michael Iverson, the studio develops motion graphics, 3D product visualization, investor presentations, and immersive digital experiences. As part of the transaction, Michael Iverson joins Netcapital as Chief Design Director and Head of AI Experience. Under the agreement, Netcapital acquired Iverson Design's f

    1/6/26 4:22:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026

    Bristol Myers Squibb (NYSE:BMY) will announce results for the fourth quarter of 2025 on Thursday, February 5, 2026. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol My

    12/18/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ALVR
    $BMY
    $DSKE
    Leadership Updates

    Live Leadership Updates

    View All

    Netcapital Inc. Announces Appointment of Rich Wheeless as CEO

    NCPL to Expand Beyond Traditional Securities into Crypto and Blockchain-Enabled Investments BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)) (the "Company"), a digital private capital markets ecosystem, today announced the appointment of Rich Wheeless as CEO. Former CEO, Martin Kay, will remain as an advisor to the company. Mr. Wheeless is a seasoned executive with more than 20 years of financial leadership and corporate management experience across multiple industries in both public and private enterprises. He was most recently the Chief Executive Officer of a publicly traded logistics and warehousing solutions company and has served as an active inves

    12/8/25 5:00:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Advent Technologies Commissions Arxicon as Master Planner for RHyno Project

    LIVERMORE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Advent Technologies Holdings, Inc. (NASDAQ:ADN), through its wholly owned subsidiary Advent Technologies S.A., is pleased to announce its official collaboration with Arxicon, a leading Greek engineering and project management firm, for the development of its master plan for the RHyno Project. The RHyno Project officially commenced on April 1, 2025, and is funded by the EU Innovation Fund. It involves the development and construction of the facility and key infrastructure for manufacturing innovative fuel cells, electrolysers, and their critical components, including Advent's cutting-edge Membrane Electrode Assembly (MEA) technology, at

    10/27/25 8:45:00 AM ET
    $ADN
    Industrial Machinery/Components
    Miscellaneous

    Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

    Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team Samit Hirawat, M.D., Executive Vice President, to step down from his role on August 1 and will depart BMS on November 1 Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company's early-stage and late-stage product development across all therapeutic areas. "We are thrilled to welcome Cristian to Bristol Myers Squibb," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "His d

    7/25/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADN
    $ALVR
    $BMY
    $DSKE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Netcapital Inc.

    SC 13G/A - Netcapital Inc. (0001414767) (Subject)

    11/14/24 7:25:20 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Netcapital Inc.

    SC 13G/A - Netcapital Inc. (0001414767) (Subject)

    11/14/24 4:23:19 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    SEC Form SC 13G filed by AlloVir Inc.

    SC 13G - Allovir, Inc. (0001754068) (Subject)

    10/11/24 4:02:13 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care